Results 81 to 90 of about 80,266 (330)

Comparative CNS Pharmacology of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis

bioRxiv
Tolebrutinib is a covalent BTK inhibitor designed and selected for potency and CNS exposure to optimize impact on BTK-dependent signaling in CNS-resident cells.
Timothy J. Turner, Priscilla Brun, Ross Gruber, D. Ofengeim   +3 more
semanticscholar   +1 more source

Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Blood, 2019
Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open--label, multicenter, phase1 study, patients in part 1 (3+3) dose escalation) had relapsed/refractory B-cell malignancies and received ...
C. Tam, J. Trotman, Stephen Samuel Opat, J. Burger, G. Cull, D. Gottlieb, R. Harrup, P. Johnston, P. Marlton, J. Muñoz, J. Seymour, D. Simpson, A. Tedeschi, R. Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane E. Huang, W. Novotny, Lai Wang, A. Roberts   +20 more
semanticscholar   +1 more source

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Journal of Hematology & Oncology, 2020
Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic ...
Wei Xu, Shenmiao Yang, K. Zhou, L. Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Dao-bin Zhou, Jianda Hu, R. Feng, Haiwen Huang, M. Ji, Haiyi Guo, Jane E. Huang, W. Novotny, S. Feng, Jianyong Li   +16 more
semanticscholar   +1 more source

Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib

JCI Insight, 2022
Recent clinical trials have shown promising results for the next-generation Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS).
L. Rijvers, Jamie van Langelaar, Laurens Bogers, M. Melief, Steven C. Koetzier, Katelijn M. Blok, A. Wierenga-wolf, H. D. de Vries, J. Rip, O. Corneth, R. Hendriks, R. Grenningloh, U. Boschert, J. Smolders, Marvin M. van Luijn   +14 more
semanticscholar   +1 more source

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases

Медицинская иммунология, 2023
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina, N. B. Serebryanaya, T. V. Glazanova, M. A. Mikhalyova, S. V. Voloshin   +4 more
doaj   +1 more source

Theory of electron transport in normal metal/superconductor junctions [PDF]

, 2000
On the basis of the Keldysh method of non-equilibrium systems, we develop a theory of electron tunneling in normal-metal/superconductor junctions. By using the tunneling Hamiltonian model (being appropriate for the tight-binding systems), the tunneling ...
Hu, Chia-Ren, Yan, Xin-Zhong, Zhao, Hongwei   +2 more
core   +2 more sources

BTK drives neutrophil activation for sterilizing antifungal immunity

Journal of Clinical Investigation
We describe a previously unappreciated role for Bruton’s tyrosine kinase (BTK) in fungal immune surveillance against aspergillosis, an unforeseen complication of BTK inhibitors (BTKi) used for treating B cell lymphoid malignancies.
Jigar V. Desai, Marissa A. Zarakas, Andrew L. Wishart, M. Roschewski, Mariano A. Aufiero, Ágnes Donkó, G. Wigerblad, Neta Shlezinger, Markus Plate, M. R. James, Jean K Lim, G. Uzel, Jenna R. E. Bergerson, Ivan Fuss, Robert A Cramer, Luis M Franco, Emily S Clark, Wasif N Khan, Daisuke Yamanaka, Georgios Chamilos, J. El-Benna, Mariana J. Kaplan, Louis M. Staudt, Thomas L. Leto, Steven M. Holland, Wyndham H Wilson, Tobias M. Hohl, M. Lionakis   +27 more
semanticscholar   +1 more source

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance

Blood and Lymphatic Cancer : Targets and Therapy, 2022
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has changed significantly since the development of oral Bruton’s tyrosine kinase (BTK) inhibitors.
F. St-Pierre, Shuo Ma
semanticscholar   +1 more source

Radial capacity and hemodynamics evaluation in vitro and implantable feasibility validation in vivo of thinner bioresorbable polymer vascular stents

BMEMat, EarlyView.
A series of in vitro experiments, numerical simulations and in vivo experiments were conducted to jointly evaluate the effects of different thicknesses of bioabsorbable polymer vascular stents on their radial capacity, hemodynamics and in vivo outcomes.
Chong Chen, Tao Li, Zhongyou Li, Jingyuan Zhou, Zhuo Zhang, Yan Xiong, Rifang Luo, Yu Chen, Yunbing Wang, Ping Fu   +9 more
wiley   +1 more source

-----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts.

Blood, 2022
Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK and have become a preferred CLL therapy.
Deyi Zhang, Hailey M. Harris, Jonathan Chen, J. Judy, Gabriella James, Aileen M. Kelly, J. Mcintosh, A. Tenn-McClellan, Eileen Ambing, Ying Siow (May) Tan, Hao Lu, S. Gajewski, M. Clifton, Stephanie L. Yung, Daniel W. Robbins, Mehdi Piroozia, Sigrid S. Skånland, E. Gaglione, Maissa Mhibik, Chingiz Underbayev, I. Ahn, Clare Sun, S. E. Herman, M. Noviski, A. Wiestner   +24 more
semanticscholar   +1 more source